Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
V-type proton ATPase subunit S1 (ATP6AP1, also known as Ac45) is an essential accessory subunit of the vacuolar-type H+-ATPase (V-ATPase) complex, a multi-subunit proton pump responsible for acidifying intracellular organelles such as lysosomes, endosomes, and secretory vesicles. ATP6AP1 plays a critical role in V-ATPase assembly, stability, and targeting to specialized subcellular compartments, thereby regulating luminal pH, vesicular trafficking, and autophagy. Dysregulation of ATP6AP1 is implicated in several human pathologies; its overexpression is associated with poor prognosis, chemoresistance, and immunosuppression in various cancers, including breast, colorectal, and hepatocellular carcinomas, while loss-of-function mutations cause a congenital disorder of glycosylation characterized by immunodeficiency, hepatopathy, and cognitive impairment. Pharmacologically, ATP6AP1 has emerged as a promising therapeutic target, with the FDA-approved drug niclosamide recently identified as a direct degrader that destabilizes ATP6AP1 to suppress tumor progression and overcome drug resistance. Additionally, classical V-ATPase inhibitors like bafilomycin A1 and concanamycin A disrupt the function of the V-complex containing ATP6AP1, highlighting its significance in therapeutic strategies targeting organelle acidification and autophagy.
Targeted protein degradation of ATP6AP1 to suppress tumor progression and enhance chemotherapy sensitivity, or indirect inhibition of the V-ATPase proton pump complex to disrupt organelle acidification and block autophagic flux.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on V-type proton ATPase subunit S1 (ATP6AP1).